---
title: "Cardiol Therapeutics says Phase II recurrent pericarditis data for CardiolRx published in JAHA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292616072.md"
description: "Cardiol Therapeutics announced the publication of Phase II MAvERIC trial results for CardiolRx in the Journal of the American Heart Association. The data demonstrated rapid, sustained reductions in pericarditis pain and inflammation, fewer annual episodes, and favorable safety profiles. This publication supports the ongoing pivotal Phase III MAVERIC trial, which is nearing enrollment completion."
datetime: "2026-07-14T11:27:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292616072.md)
  - [en](https://longbridge.com/en/news/292616072.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292616072.md)
generator: "portal-rs"
---

# Cardiol Therapeutics says Phase II recurrent pericarditis data for CardiolRx published in JAHA

-   Cardiol Therapeutics reported publication of Phase II MAvERIC results for CardiolRx in the Journal of the American Heart Association. \* Data showed rapid, sustained reductions in pericarditis pain and inflammation, fewer annual pericarditis episodes, and favorable safety and tolerability. \* Publication supports the pivotal Phase III MAVERIC trial, with enrollment nearing completion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiol Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607140727PR\_NEWS\_USPR\_\_\_\_\_TO03740) on July 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CRDL.US](https://longbridge.com/en/quote/CRDL.US.md)

## Related News & Research

- [VivoSim Labs plans rat liver model expansion for NAMkind platform](https://longbridge.com/en/news/297649874.md)
- [Cytosorbents Real-World Data Shows CytoSorb Reduces Severe Bleeding In Cardiac Surgery](https://longbridge.com/en/news/297786128.md)
- [Moleculin Biotech highlights interim Phase 3 AML data for annamycin showing 36% CR, 54% CRc in pooled arms](https://longbridge.com/en/news/297668239.md)
- [RWAperp Launches AI-Executed Perpetuals Venue on OKX’s X Layer](https://longbridge.com/en/news/297960124.md)
- [SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals](https://longbridge.com/en/news/298195637.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**